Mark was formerly with Index Ventures, which he joined in 2005 as a Venture Partner. He has been involved in many investments, including Comentis, Molecular Partners (SWX:MOLN), PanGenetics (acquired by Abbott), ProFibrix (acquired by The Medicines Company) and Versartis (Nasdaq: VSAR). He is an advisor to the Utrecht University Technology Transfer Office and Holdings. He has worked for, managed and founded a number of early-stage biopharmaceutical companies in the field of innovative novel biopharmaceuticals.
Mark graduated in Biochemistry and has a PhD from the University of Amsterdam.